Evaluation of immunotherapy using dendritic cells and tumor antigen peptide against patients with malignant gliomas

点击翻译按钮获取中文摘要

Recently SART-3 has been shown to be an tumor-associated antigen of malignant gliomas. In this study, we evaluated whether immunological responses are elicited or not after immunization of the patients with gliomas using dendritic cells (DC) pulsed with SART-3 antigen peptide.Eight glioma patients whose HLA types were HLA-A201 and -A24 were selected as candidates for immunotherapy. Peripheral blood lymphocytes (PBL) were separated, DC were induced using several cytokines, DC were pulsed with SART-3 antigen peptide, and then the DC were injected subcutaneously at the neck. The patients received 4 cycles of DC therapy. Before and after the DC Injection, PBL were separated and kept in frozen. Presence of the lymphocytes that are able to recognize the SART-3 antigen peptide was evaluated by enzyme-linked immunospot (ELISPOT) assay. One patient showed some response after the fourth DC immunization, however, 6 patients did not. One patient is waiting for the evaluation.These results indicate that the immunotherapy using DC cells pulsed with SART-3 antigen peptide can induce the lymphocytes which recognize the SART-3 antigen in some glioma patients.